Immunovant Inc

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

AdaptHealth Corp

DraftKings

Social Capital Hedosophia Holdings Corp. II 

Repay Holdings Corp

Virgin Galactic

Workhorse Group

In October, ther may be price pullbacks in shares of SPAC IPOs, offering long-term investors better entry points. The post 7 of the Most Interesting New SPACs to Take a Chance On appeared first on InvestorPlace.

7 of the Most Interesting New SPACs to Take a Chance On

NEW YORK, Sept.  04, 2020  (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of 6,060,606 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 790,513 additional shares of common stock, at a price to the public of $33.00 per share. The aggregate gross proceeds to Immunovant from the offering were approximately $200.0 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock were sold by Immunovant.

Immunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Hot biotech stock Immunovant on Wednesday priced its secondary offering of 5.27 million shares at $33 per share, as IMVT stock trades near record highs after a rival attracted a big suitor.
The post Immunovant, Following Rival's Acquisition News, Prices Stock Offering appeared first on Investor's Business Daily.

Immunovant, Following Rival's Acquisition News, Prices Stock Offering

NEW YORK, Sept.  02, 2020  (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced the pricing of its underwritten public offering of 5,270,093 shares of its common stock at a price to the public of $33.00 per share. The aggregate gross proceeds to Immunovant from the offering are expected to be approximately $173.9 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Immunovant. The offering is expected to close on September 4, 2020, subject to customary closing conditions. In connection with this offering, Immunovant has granted the underwriters a 30-day option to purchase up to an aggregate of 790,513 additional shares of common stock on the same terms and conditions.  If the underwriters exercise this option in full, the aggregate gross proceeds to Immunovant from the offering would be approximately $200.0 million, before deducting underwriting discounts and commissions and offering expenses.

Immunovant Announces Pricing of Public Offering

Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.

Immunovant Up on Positive Data From Myasthenia Gravis Study

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a study of OmniAb-derived IMVT-1401 in patients with myasthenia gravis (MG).

Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis

Company to Host Conference Call on August 25, 2020 at 8:30am EDT Company to Host Conference Call on August 25, 2020 at 8:30am EDT

Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis

Dr. Elliott previously served as Vice President of Immunology Scientific Innovation at J&J and has led the clinical development of multiple blockbuster immunology products Dr. Elliott previously served as Vice President of Immunology Scientific Innovation at J&J and has led the clinical development of multiple blockbuster immunology products

Immunovant Appoints Michael Elliott Chief Scientific Officer

Immunovant Inc (NASDAQ: IMVT) shares were ripping higher Wednesday in a sympathy move.

Why Immunovant Could Benefit From The J&J-Momenta Deal

NEW YORK, Aug.  12, 2020  (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal first quarter ended June 30, 2020.  Immunovant ended the quarter with approximately $280.3 million in cash.    

Immunovant Reports Financial Results for the Quarter Ended June 30, 2020

BiomX Inc.

Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.

Why Some Biotech Companies Are Turning to SPACs

NEW YORK, June  29, 2020  (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal fourth quarter and fiscal year ended March 31, 2020. As of today, June 29, 2020, Immunovant’s cash balance is approximately $280.4 million. “We recently strengthened our balance sheet, facilitating the continued advancement of IMVT-1401 as we progress towards our goal of enabling normal lives for patients with autoimmune diseases,” said Pete Salzmann, M.D., Chief Executive Officer of Immunovant. 

Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis

Immunovant (IMVT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Immunovant (IMVT) Stock Might be a Great Pick

As of late, it has definitely been a great time to be an investor of Immunovant

Will Immunovant Continue to Surge Higher?

NEW YORK, May  14, 2020  (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced that holders of its 11.5 million outstanding warrants will have until 5:00 p.m., New York City time, on June 15, 2020 to exercise their warrants.  The 11.5 million warrants are exercisable for an aggregate of 5.75 million shares of Immunovant’s common stock at a price of $11.50 per share, representing a total of $66.125 million in potential proceeds to Immunovant.  Pursuant to the warrant agreement, Immunovant is entitled to redeem all of the outstanding warrants if the last sale price of its common stock is at least $16.50 per share on each of 20 trading days within any 30 trading-day period.  This share price performance target was achieved on May 11, 2020.  Any warrants that remain unexercised immediately after 5:00 p.m., New York City time, on June 15, 2020 will be void and no longer exercisable, and the holders of those warrants will be entitled to receive $0.01 per warrant. 

Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement

NEW YORK, April  16, 2020  (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of 9,613,365 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,253,917 additional shares of common stock, at a price to the public of $14.50 per share. The aggregate gross proceeds to Immunovant from the offering were approximately $139.4 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock were sold by Immunovant.

Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunovant (IMVT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Immunovant (IMVT) Catches Eye: Stock Jumps 5%

News for Immunovant Inc Stock (IMVT)